4.89
+0.26(+5.62%)
Currency In USD
| Previous Close | 4.63 |
| Open | 4.69 |
| Day High | 4.98 |
| Day Low | 4.5 |
| 52-Week High | 4.98 |
| 52-Week Low | 1.01 |
| Volume | 1.25M |
| Average Volume | 1.38M |
| Market Cap | 175.97M |
| PE | -2.57 |
| EPS | -1.9 |
| Moving Average 50 Days | 3.48 |
| Moving Average 200 Days | 2.19 |
| Change | 0.26 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $278 as of August 23, 2025 at a share price of $4.89. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $772.51 as of August 23, 2025 at a share price of $4.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering Announces $25 Million Private Placement
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreem
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-la
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
GlobeNewswire Inc.
Jun 17, 2025 10:00 AM GMT
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% diseas